Discovery research resources

Stahl, M., Cuba, W. and Kansy, M. (2006) Integrating molecular design resources within modern drug discovery research the Roche experience. Drug Discovery Today, 11, 326-333. 

Moreover, the discovery of effective agents to treat infectious diseases such as malaria and tuberculosis is inherently difficult - bacterial resistance and viral mutations are common, so that therapies have very limited efficacy, and a discovery platform in infectious disease is a multi-year commitment of financial and other research resources. Again, developmental failures are expensive and R D expenditures are what economists call "sunk costs," meaning that the costs are not recoverable in the future. 

There has been explosive growth in the number of disease models in recent decades, especially in the field of the knockouts and transgenic rodents. A description of the most frequently used models alone would take a separate volume, and even that would be outdated within no time. Information on the selection of models and background data can easily be found on the Internet. The US National Center for Research Resources (NCRR) provides overviews and links [12], In addition the main providers of laboratory animals have very useful information on their Web sites. Readers looking for overviews on animal models per disease may find useful information in the Drug Discovery Today Disease Models review journal (http //www.drugdiscoverytoday.com). 

Stahl M, Guba W, Kansy M. Integrating molecular design resources within modem dmg discovery research The Roche experience. Drug Discov Today 2006 11 326-333. 

Gene Discovery Research Group, RIKEN Center for Sustainable Resource Science, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan e-mail kazuo.shinozaki riken.jp... 

Purpose The mission of the National Institute of Neurological Disorders and Stroke (NINDS) Office of Translational Research is to facilitate the pre-clinical discovery and development of new therapeutic interventions for neurological disorders. The Office supports pre-clinical projects from the discovery of candidate therapeutics through IND and Investigational Device Exemption (IDE) applications to the FDA. This is accomplished through both access to NINDS contract resources and direct funding mechanisms. 

We thank Dr. Thomas Morris, President and CEO, and Mr. Matthew Sooley of Northern Superior Resources for providing information on, and access to the site. Field expenses and analytical costs were supported by an NSERC Discovery Grant. Funding for this project was also provided in part by an Ontario Graduate Scholarship (support for Jamil Sader s Ph.D.) and a student research grant from the Society of Economic Geologists. 

---